Trial Comparing High-Velocity Nasal Insufflation Versus Non-Invasive Ventilation for Respiratory Failure in Guillain-Barré Syndrome

What this Trial Is About

This research aims to evaluate respiratory support methods for adult patients with Guillain-Barré syndrome who experience severe breathing problems. Guillain-Barré syndrome is a rapid-onset nerve disorder causing muscle weakness, sometimes leading to respiratory failure requiring urgent support. The study compares two types of non-invasive breathing assistance to determine which helps more patients avoid needing invasive breathing machines by Day 30. Secondary goals include assessing comfort, hospital stay length, breathing independence, and survival rates within 30 days. The study compares high-velocity nasal cannula (HVNC) therapy, which delivers heated and humidified air at 35-60 liters per minute through nasal prongs, to bi-level non-invasive ventilation (NIV) that provides two pressure levels through a mask. NIV uses inspiratory positive airway pressure of 10-16 cmH2O and expiratory positive airway pressure of 5-8 cmH2O, with oxygen levels adjusted to keep blood oxygen saturation at or above 92%. Both treatments are delivered continuously with adjustments based on patient needs. Participants will be monitored from 48 hours after starting treatment and daily for 28 days, tracking how long they successfully use non-invasive support without needing invasive ventilation. Researchers will assess patient comfort, length of ICU and hospital stays, days of independent breathing, and survival within 30 days. The study starts in August 2025 and will enroll 70 adults, with ongoing evaluation until November 2026.

Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome